Methods for obtaining compounds from a plant or fungus material, respective compositions, and uses thereof

Abstract

Disclosed herein is a method for obtaining compounds and compositions from plant and fungus materials by thermal treatment, affinity capture, filtration, and release through multi-phasic transitions between gas, solid, and liquid states. The compounds of interest are obtained by manipulating the temperature and pressure of the heating chamber. The compounds in gas phase are passed through an affinity medium which captures the compounds of interest in either solid or liquid phase by exposing the compound of interest to the localized micro-affinity environment of the medium. The compounds are separated from the medium using direct competition with solvent or buffers optimized for the specific chemical properties of compounds.

1 - 96 . (canceled) 
     
     
         97 . A liquid or solid composition, comprising cannabidiol, cannabinodiol, and at least one compound selected from o-methylcannabidiol, o-methylcannabinol, o-propylcannabinol, and o-pentylcannabinol. 
     
     
         98 . The composition of  claim 97 , comprising from about 10 wt. % to about 70 wt. % cannabidiol and from about 1 wt. % to about 20 wt. % cannabinodiol. 
     
     
         99 . The composition of  claim 98 , comprising from about 20 wt. % to about 60 wt. % cannabidiol and from about 1 wt. % to about 5 wt. % cannabinodiol. 
     
     
         100 - 101 . (canceled) 
     
     
         102 . A liquid or solid composition, comprising Δ9-tetrahydrocannabinol, cannabinol, and at least one compound selected from o-methylcannabinol, o-propylcannabinol, and o-pentylcannabinol. 
     
     
         103 . The composition of  claim 102 , comprising from about 1.0 wt. % to about 15 wt. % Δ9-tetrahydrocannabinol and from about 5 wt. % to about 50 wt. % cannabinol. 
     
     
         104 . (canceled) 
     
     
         105 . The composition of  claim 102 , comprising at least 1 wt. % Δ9-tetrahydrocannabinol and at least 20 wt. % cannabinol. 
     
     
         106 . (canceled) 
     
     
         107 . The composition of  claim 97 , wherein the at least one compound selected from o-methylcannabidiol, o-methylcannabinol, o-propylcannabinol, and o-pentylcannabinol is present in an amount from 0.05 wt. % to 1 wt. %. 
     
     
         108 . (canceled) 
     
     
         109 . The composition of  claim 102 , wherein the at least one compound selected from o-methylcannabinol, o-propylcannabinol, and o-pentylcannabinol is present in an amount from 0.05 wt. % to 1 wt. %. 
     
     
         110 . (canceled) 
     
     
         111 . A solid or liquid composition comprising cannabinol, Δ9-tetrahydrocannabinol, exo-tetrahydrocannabinol and optionally Δ10-tetrahydrocannabinol, wherein the cannabinol is present in the composition from about 5 wt. % to about 50 wt. %, the Δ9-tetrahydrocannabinol is present in the composition from about 1 wt. % to about 15 wt. %, the exo-tetrahydrocannabinol is present in the composition from about 1 wt. % to about 5 wt. % and if present the Δ10-tetrahydrocannabinol is present from about 1 wt. % to about 5 wt. %. 
     
     
         112 . The composition of  claim 111 , wherein the cannabinol is present in the composition from about 5 wt. % to about 30 wt. %, the Δ9-tetrahydrocannabinol is present in the composition from about 5 wt. % to about 10 wt. %, and the exo-tetrahydrocannabinol is present in the composition from about 1.5 wt. % to about 3 wt. %. 
     
     
         113 . A solid or liquid composition comprising cannabinol, Δ9-tetrahydrocannabinol, and Δ10-tetrahydrocannabinol, wherein the cannabinol is present in the composition from about 5 wt. % to about 50 wt. %, the Δ9-tetrahydrocannabinol is present in the composition from about 1 wt. % to about 15 wt. %, and the Δ10-tetrahydrocannabinol is present in the composition from about 1 wt. % to about 5 wt. %. 
     
     
         114 . The composition of  claim 113 , wherein the cannabinol is present in the composition from about 5 wt. % to about 30 wt. %, the Δ9-tetrahydrocannabinol is present in the composition from about 5 wt. % to about 10 wt. %, and the Δ10-tetrahydrocannabinol is present in the composition from about 1.5 wt. % to about 3 wt. %. 
     
     
         115 - 145 . (canceled) 
     
     
         146 . A method of any one or more of:
 reducing anxiety and promoting relaxation in a subject in needs thereof;   increasing sleep quality in a subject in needs thereof; and   treating a condition in a subject in needs thereof, the condition selected from:
 an autoimmune disorder, an inflammatory disorder, chronic pain, a mood disorder, or a developmental disorder, 
 the method comprising administering a therapeutically effective amount of a liquid or solid composition, comprising cannabidiol, cannabinodiol, and at least one compound selected from o-methylcannabidiol, o-methylcannabinol, o-propylcannabinol, and o-pentylcannabinol. 
   
     
     
         147 . The method of  claim 146 , wherein the condition is selected from fibromyalgia, an Ehlers-Danlos syndrome, multiple sclerosis, epilepsy, Parkinson's disease, Huntington's disease, Alzheimer's disease, stroke, hypertension, atherosclerosis, muscle spasms, an inherited neuropathy, Crohn's disease, psoriasis, arthritis, Lyme disease, anxiety, post-traumatic stress disorder, an autism spectrum disorder, a schizophrenia spectrum disorder, and chronic migraine. 
     
     
         148 - 149 . (canceled) 
     
     
         150 . The method of  claim 146 , wherein the condition is selected from spasticity, anorexia, nausea, pain, nicotine addiction, acne, fibromyalgia, anxiety, inflammation, schizophrenia or insomnia. 
     
     
         151 - 158 . (canceled) 
     
     
         159 . The method of  claim 146 , wherein the composition is administered orally or via inhalation. 
     
     
         160 . (canceled) 
     
     
         161 . A liquid or solid composition, comprising cannabidiol, cannabinodiol, and at least one compound selected from cannabicyclol (CBL), cannabichromene (CBC), cannabicitran (CBT), Δ9-tetrahydrocannabinol and exo-tetrahydrocannabinol. 
     
     
         162 . The composition of  claim 161 , comprising from about 20 wt. % to about 60 wt. % cannabidiol and from about 1 wt. % to about 5 wt. % cannabinodiol. 
     
     
         163 . The composition of  claim 161 , wherein the at least one compound is cannabicitran. 
     
     
         164 . The composition of  claim 161 , wherein the at least one compound is exo-tetrahydrocannabinol. 
     
     
         165 . The composition of  claim 161 , wherein the at least one compound is cannabichromene. 
     
     
         166 . The composition of  claim 161 , wherein the at least one compound is Δ9-tetrahydrocannabinol.